Tiny RNA Molecule May Explain Why Some People Resist Tuberculosis Infection

Tuberculosis remains one of humanity’s oldest and deadliest adversaries, yet a curious biological puzzle has persisted for decades: not everyone exposed to Mycobacterium tuberculosis, the bacterium that causes the disease, becomes infected. Some people live in close quarters with actively sick family members, sharing air, meals, and living space for months, and still never test positive for infection. A new study published in PLOS Pathogens offers a compelling molecular explanation for this phenomenon, pointing to a small regulatory RNA molecule called microRNA-1246 as a key player in natural resistance to tuberculosis infection.

The research, led by Ashutosh Tripathi and Deepak Tripathi together with Ramakrishna Vankayalapati and an international team of collaborators, focused on a uniquely valuable group of study participants: household contacts of patients with active pulmonary tuberculosis. The team recruited 460 such contacts from 443 index cases—people who had documented, sustained exposure to contagious tuberculosis patients in their own homes. Because these individuals faced genuine, repeated exposure to the bacterium, any who remained free of infection represented natural experiments in protective immunity that laboratory models alone could never replicate.

To distinguish resistance from simple luck of exposure, the researchers followed the participants for two years, monitoring infection status with interferon-gamma release assays, or IGRAs, the blood tests that detect cellular immune responses to M. tuberculosis. Of the 460 contacts enrolled, 293 individuals—64.8 percent of the cohort—remained IGRA-negative throughout the entire follow-up period. The team labeled these persistent test-negatives as nonconverters. In contrast, other participants either converted to IGRA-positive during the study, indicating new infection, or progressed toward active disease. This longitudinal design allowed the investigators to compare people who resisted infection against those who succumbed to it, despite similar exposure conditions.

The centerpiece of the study was whole-transcriptome sequencing, a technique that captures the complete landscape of RNA molecules expressed in cells, performed on samples collected at baseline, when participants first enrolled, and again at 24 months of follow-up. By profiling the small RNA repertoire in these matched samples, the researchers searched for microRNAs—short, roughly 22-nucleotide RNA strands that do not encode proteins but instead regulate gene expression after transcription—that distinguished resistant individuals from susceptible ones. Two candidates emerged from this screen with striking consistency: microRNA-1246, which was downregulated in the resistant nonconverters, and microRNA-125b, which was upregulated in the same group relative to converters and progressors.

MicroRNAs function by binding to complementary sequences in messenger RNA targets, typically suppressing the production of the proteins those targets encode. Because a single microRNA can regulate dozens or even hundreds of genes, changes in microRNA levels can rewire entire cellular pathways. The downregulation of microRNA-1246 in resistant contacts suggested that lifting this molecule’s brake on certain genes might be part of what shields those individuals from infection. Confirmation studies validated the sequencing results, establishing the differential expression of the two microRNAs as a reproducible signature associated with resistance rather than a statistical artifact.

To understand how microRNA-1246 actually influences the battle against the tubercle bacillus, the team turned to mechanistic experiments in macrophages, the immune cells that form the first line of defense against M. tuberculosis and, paradoxically, the very cells the bacterium colonizes. Macrophages engulf inhaled bacilli and normally destroy them, but M. tuberculosis has evolved sophisticated strategies to survive and replicate inside these cells, including manipulating the host cell’s metabolism to create a hospitable niche. Combining proteomics—the large-scale analysis of the proteins present in cells—with computational target prediction, the investigators identified the molecule through which microRNA-1246 exerts its effects: a protein called alpha/beta hydrolase domain-containing protein 2, or ABHD2.

ABHD2 belongs to a large family of hydrolase enzymes and, in this context, functions as a lipase involved in lipid metabolism. The connection to tuberculosis is more than incidental. M. tuberculosis is a lipid-hungry pathogen; during infection it co-opts macrophage lipid handling, promoting the accumulation of cholesterol droplets and fatty acids that the bacterium can consume. By targeting ABHD2, microRNA-1246 effectively modulates the lipase activity available to support this metabolic hijacking. When the researchers used a microRNA-1246 inhibitor to block the molecule’s activity in infected macrophages, the result was a measurable reduction in the growth of M. tuberculosis within the cells—direct experimental evidence that dampening microRNA-1246 strengthens the macrophage’s ability to restrain the pathogen.

The metabolic story ran deeper still. Inhibition of microRNA-1246 did more than alter lipid processing; it increased glycolytic activity, shifting the macrophage’s energy metabolism toward the rapid sugar-burning mode associated with inflammatory, microbe-killing immune activation. Immunologists describe this reprogramming as a metabolic shift, and it matters because macrophage metabolism and antimicrobial function are tightly intertwined. A macrophage running on glycolysis is generally better equipped to clear intracellular pathogens than one locked into a quiescent, lipid-storing state that favors bacterial survival. In other words, blocking microRNA-1246 appears to push macrophages into a configuration conducive to pathogen clearance, explaining at the cellular level why the resistant contacts who naturally showed lower levels of this microRNA fended off infection.

The findings carry significant therapeutic implications. Current tuberculosis control relies on antibiotics and the Bacillus Calmette-Guérin vaccine, whose protection against pulmonary tuberculosis in adults is variable, and multidrug-resistant strains continue to complicate treatment worldwide. A host-directed therapy—one that bolsters the patient’s own immune machinery rather than attacking the bacterium directly—could complement existing drugs, shorten treatment, or help protect the most exposed populations. Because microRNAs can be targeted with chemically synthesized inhibitor molecules, the demonstration that a microRNA-1246 inhibitor curbs M. tuberculosis growth in macrophages suggests a concrete pharmacological avenue. The study’s authors highlight these microRNA-based strategies as a promising direction for enhancing immunity against the pathogen, though the work so far rests on human association data and cell-based mechanistic experiments rather than clinical trials.

Equally important is what the study says about human immunological variation. Resistance to M. tuberculosis infection has long been suspected to have a genetic and regulatory basis, and this work grounds that suspicion in a specific, testable molecular mechanism linking a microRNA, a lipid-metabolism enzyme, and cellular energetics. The two-year prospective design, the size of the household-contact cohort, and the convergence of transcriptomic, proteomic, and functional evidence together make a strong case that microRNA-1246 is genuinely involved in resistance rather than merely correlated with it. As researchers pursue the next steps—validating the pathway in additional models and exploring whether microRNA-125b contributes independently to the resistant phenotype—the study stands as a vivid example of how studying the people who do not get sick can reveal defenses that the rest of us might one day borrow.

Subject of Research: The role of microRNA-1246 in macrophage lipid metabolism and resistance to Mycobacterium tuberculosis infection

Article Title: MicroRNA-1246 regulates macrophage lipid metabolism and is involved in resistance to human Mycobacterium tuberculosis infection

Article References: Tripathi, A., Neela, V. S. K., Radhakrishnan, R. K., Devalraju, K. P., Bogam, A. K., Mukherjee, T., Mallidi, V., Vankayalapati, A., Ansari, M. S. S., Arana, C., Joshi, S., Singh, K. P., Valluri, V. L., Vankayalapati, R., & Tripathi, D. (2026). MicroRNA-1246 regulates macrophage lipid metabolism and is involved in resistance to human Mycobacterium tuberculosis infection. PLOS Pathogens, 22(10), e1014454. https://doi.org/10.1371/journal.ppat.1014454

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014454

Keywords: tuberculosis, microRNA-1246, macrophages, lipid metabolism, ABHD2, glycolysis, household contacts, host-directed therapy, PLOS Pathogens, Mycobacterium tuberculosis, innate immunity, transcriptomics